US-Aligned Clinical Bridging Program in COPD and Lung Fibrosis

RespiRAX Pharma is advancing a US-aligned clinical bridging study Targeting COPD and Lung Fibrosis caused by Viral, Bacterial and Fungal infections - Significant area of unmet medical need with limited disease-modifying therapies.

Phase II–III Bridge Study

US FDA–Approved CRO

FDA/EMA Aligned

Medical research partnership and collaboration

Partnering & Investment Opportunity

Our proposed program is designed as a Phase II–III bridge study, to be conducted through a US FDA–approved Clinical Research Organization (CRO) in India. The study framework is strategically aligned with both FDA and EMA regulatory pathways, enabling efficient progression toward global registration and commercialization.

Late-Stage Clinical Partnering Opportunity

We welcome discussions with multinational pharmaceutical companies and Investors seeking access to a clinically validated asset transitioning into COPD and lung fibrosis, as well as the opportunity to participate in a Phase II–III bridge study designed for regulatory acceptance and inclusion in global respiratory portfolios.

Access to a clinically validated asset transitioning into COPD and Lung Fibrosis
Participation in a Phase II–III bridge study designed for regulatory acceptance
Programs aligned with US FDA expectations and global respiratory portfolios
Clinical data available under NDA

Confidential & Structured Engagement

Step 1:Mutual NDA prior to disclosure

Step 2:Secure access to clinical, regulatory & commercial materials

Step 3:Direct engagement with senior leadership & clinical experts

Clinical & Regulatory Overview

Target:COPD & Lung Fibrosis from Virus, Bacterial and Fungal Infections

Study Design:Phase II–III bridge study

CRO:US FDA–approved, based in India

Regulatory:FDA / EMA aligned pathways

Objective:Global registration & commercialization

Partner with RespiRAX Pharma to bring innovative, life-changing therapies to patients worldwide.

Get in Touch